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Background: Alpha1-antitrypsin (AAT) deficiency, although largely under-diagnosed, is the un-
derlying cause of approximately 1% of COPD cases. Lack of awareness leads to long delays in
diagnostic testing. Subsequently, lifestyle and treatment choices with potentially positive ef-
fects on prognosis may be postponed.
Methods: Data on the testing and diagnostic practices for AAT deficiency were derived from
the University of Pavia, Italy, and the University of Marburg, Germany. In addition, a survey
of physicians was undertaken to explore their awareness and attitudes toward AAT deficiency.
Results: In Pavia and Marburg, 125 and 729 patients, respectively, were identified with severe
AAT deficiency between July 2006 and June 2011. The median time interval between the onset
of symptoms and diagnosis was 6 years (interquartile range [IQR], 11; range, 0e40) and 7 years
(IQR, 13; range, 0e73), respectively. Augmentation therapy was initiated almost immediately
in Germany while treatment was delayed by 3 months in Italy (IQR, 5.25; range, 1e118). Survey
data (Italy, nZ 181; Germany, nZ 180) revealed that pulmonologists had greater knowledgeributed under the terms of the Creative Commons Attribution-NonCommercial-No Derivative Works
ial use, distribution, and reproduction in any medium, provided the original author and source are
4215866451; fax: þ49 64215868987.
ni-marburg.de (T. Greulich), stefania.ottaviani@yahoo.it (S. Ottaviani), robert.bals@uks.eu (R. Bals),
, claus.vogelmeier@med.uni-marburg.de (C. Vogelmeier), m.luisetti@smatteo.pv.it (M. Luisetti), i.
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Disease awareness of alpha1-antitrypsin deficiency 1401of AAT deficiency than internists and general practitioners, however, overall, only 18e25% of
physicians tested all COPD patients. One-third of the respondents stated that they “some-
times” offered augmentation therapy to patients diagnosed with AAT deficiency.
Conclusions: Major obstacles to AAT deficiency testing are physicians’ attitudes and lack of un-
derstanding of the condition. A greater adherence to the guidelines that recommend diag-
nostic testing of all COPD patients, coupled with simpler testing protocols, may decrease
delays and positively impact patient outcomes.
ª 2013 The Authors. Published by Elsevier Ltd. All rights reserved.Introduction
Alpha1-antitrypsin (AAT) deficiency is a co-dominant he-
reditary disorder. This condition, which is characterized by
low serum levels of alpha1-proteinase inhibitor (alpha1-PI),
was first described in 1963.1 Alpha1-PI is a 52 kDa protein
that is produced and secreted primarily in hepatocytes.2
Although present in all body tissues, the primary physio-
logic role of alpha1-PI is in the lungs, where it protects the
alveoli from damage by proteolytic enzymes through the
inhibition of neutrophil elastase.3 On a clinical level, AAT
deficiency is associated with an increased risk of developing
chronic obstructive pulmonary disease (COPD), especially in
smokers.4 Less clinically important conditions that are
associated with AAT deficiency include a greater risk of
developing liver disease, cutaneous panniculitis, vasculitis,
and Wegener’s granulomatosis.5e8
Even though AAT deficiency has been classified as a rare
disease, it is one of the most common hereditary dis-
orders.9e12 Worldwide, it has been estimated that 3.4
million individuals have an AAT genotype that leads to a
deficiency of this protein.13 Despite this, screening studies
have established that less than 10% of affected individuals
have been diagnosed.14 Evidently, AAT deficiency is sub-
stantially under-recognized. Even among the individuals
diagnosed, surveys have shown that the majority of these
diagnoses are delayed for 5e7 years, during which period
patients will typically consult several medical pro-
fessionals.15e17 Therefore, it can be assumed that, during
this time delay before their diagnosis, many patients will
have experienced a major decline in lung function.
The World Health Organization recommends testing of
all COPD patients,18 and the European Respiratory Society
and American Thoracic Society Guidelines recommend the
testing of all symptomatic adults with persistent airway
obstruction.4 Nevertheless, the discrepancy between the
estimated number of individuals with the disorder from
epidemiologic screening studies9,10,12,13 and the confirmed
numbers of diagnosed patients suggests that the recom-
mendations are not followed. A number of reasons have
been put forward to explain this, including poor awareness
of the disorder and the methods for testing; differences in
the interpretation of testing results; the multi-step
approach that is required for final diagnosis; and a
perception that existing treatments are inadequate.19
While these reasons are plausible, there is a lack of data
to support them.
Earlier diagnosis should enable patients to adapt their
lifestyles accordingly, including giving up smoking to limit
the progression of their lung damage.20 In addition, it hasbeen suggested that the decline in forced expiratory vol-
ume in 1 s and progression of emphysema development can
be attenuated by interventions such as substitution therapy
with alpha1-PI.
21e23 It is therefore important to identify the
major obstacles that prevent a more prompt diagnosis of
AAT deficiency so that they can be overcome in order to
optimize diagnostic procedures.
The aim of the present study was to explore potential
reasons for the discrepancy between the expected and
diagnosed number of patients and for the diagnostic delay.
We surveyed physicians in Italy and Germany regarding their
awareness and knowledge of AAT deficiency to explore their
opinions and attitudes towards the disease and its diagnosis.
We also present data on laboratory testing from two major
European laboratories that have specialized in the identifi-
cation of individuals with this disorder.
Methods
Study sites and participants
Descriptive data on the testing and diagnosis of AAT defi-
ciency were derived from the experience of two reference
laboratories in Europe working on national programs for the
detection of AAT deficiency, namely, the University of
Pavia, Italy, and the University of Marburg, Germany. These
two national programs for AAT deficiency detection, as well
as the diagnostic flow charts used by the two laboratories,
have already been described in detail.9,24 A description of
the type of data that were collected is shown in the
Supplementary Information.
Registry data were obtained from the national registries
of patients with AAT deficiency that have been established
in Germany25 and Italy.26,27 These organizations are mem-
bers of the international network of registries from 21
countries, the Alpha One International Registry (AIR).28 The
criterion for inclusion in the registries is the presence of
severe AAT deficiency, defined by alpha1-PI plasma con-
centrations less than 0.8 g/L. In addition, the patients must
be adults and carriers of PiZZ, PiSZ, or another deficient
genotypic variant of the gene coding for alpha1-PI.
All data from the laboratory analysis or from the regis-
tries were obtained in or refer to the period from July 1
2006 to June 30 2011.
Information collected from the online survey
In order to obtain information on the awareness and
knowledge regarding AAT deficiency and, in particular, the
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Figure 1 Components of total number of patients tested.
The percentage of patient samples that originated from family
screening programs, reported AAT levels, and were positively
diagnosed in Marburg and Pavia.
1402 T. Greulich et al.experience of physicians who are testing for the disorder,
an online survey was conducted during September 2011.
Physicians from Italy (nZ 181) and Germany (nZ 180) who
had previously agreed to participate in market research
studies were randomly invited to participate in the survey.
Pulmonologists, internal medicine specialists, and general
practice physicians from hospitals and physician offices
answered 15 questions, and the survey took them approx-
imately 10 min to complete. Participants were paid an
honorarium for completing the survey.
Physicians participating in the survey were asked about
the number of COPD patients they treat per month and
their knowledge of AAT deficiency and other respiratory
diseases. The survey also collected information on the
number of tests for AAT deficiency performed each month,
the preferred approach to testing, and the communication
between the laboratory and the physician, as well as be-
tween the physician and the patient. Finally, the survey
obtained information on the physicians’ use of augmenta-
tion therapy to treat their patients. The survey data were
analyzed by country, by physician specialty, and by hospital
or office setting. The full list of questions is shown as
Supplementary Information.
Survey data-handling and statistical analysis
Possible participant responses to the survey questions
differed depending on the type of question. These were
converted to a numerical scale, where “none at all”/“totally
disagree” Z 1, “a little”/“somewhat disagree” Z 2,
“average”/“somewhat agree” Z 3, and “very much”/
“totally agree”Z 4.
Descriptive statistics were used to summarize the data
collected from the laboratories and registries in Germany
and Italy. Categorical variables were described by fre-
quencies and percentages, and continuous variables were
expressed as median, range, and interquartile range (IQR).
Results
Phenotyping and genotyping
Between July 1 2006 and June 30 2011, 962 patients from
the University of Pavia, Italy and 9393 patients from the
University of Marburg, Germany were tested for AAT defi-
ciency (Fig. 1). Of those tested in Germany, 1102 (11.7%)
had come from family screening programs and 1450 (15.4%)
of tests reported AAT levels that had previously been
determined by serum testing. A total of 729 patients were
diagnosed with severe AAT deficiency (Fig. 2). Of those
tested in Italy, 259 (26.9%) originated from family screening
and 386 (40.1%) of tests reported AAT serum levels (Fig. 1).
In this laboratory, 125 patients were diagnosed with severe
AAT deficiency (Fig. 2).
Genotype data were collected from the patients with a
positive diagnosis of severe AAT deficiency in both refer-
ence laboratories. In Germany, 72.2% of patients had the
PiZZ genotype, with PiSZ being the second most common
(17.1%). PiZ/Rare and PiSS were detected in 4.4% and 4.3%
of the AAT-deficient patients, respectively (Fig. 2). The
PiZZ genotype was found in 60% of patients from Italy, withPiZ/Rare as the second most common (18.4%), followed by
PiSZ (11.2%). Rare genotypes that were identified in this
laboratory included PiS/Rare and PiQ0/Q0 (both prevalent
at a frequency of 3.2%).
Time intervals between onset of symptoms,
testing, and reporting of results
Data collected from established national registries
demonstrated that the median delay that index patients
experience between showing symptoms of disease and
receiving a diagnostic test is 7 years in Germany (IQR, 13;
range, 0e73) and 6 years in Italy (IQR, 11; range, 0e40). In
Germany, once a patient was tested for AAT deficiency, the
median time interval before the result was communicated
was 22 days (IQR, 20; range, 2e754), rising to 174 days (IQR,
302.5; range, 43e1146) when DNA sequencing was per-
formed. In Italy, the median time interval from testing to
results was 20 days (IQR, 13; range, 1e178) without
sequencing, and 28 days (IQR, 23; range, 7e153) when DNA
sequencing was performed.
Time lag between reporting of results and
augmentation therapy
In Germany, there was little time delay between patients
receiving their results and the start of their treatment
(median, 0; IQR, 12; range, 0e408 months). In Italy,
augmentation therapy was initiated after a median number
of 3 months (IQR, 5.25; range, 1e118) after the results had
been reported.
Results from the online survey
The composition of the respondents, by specialty, practice
setting, and by number of COPD patients seen per month, is
shown in Table 1.
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Figure 2 Genotypes of AAT-deficient individuals diagnosed from testing in Marburg, Germany, and Pavia, Italy.
The frequencies of the AAT deficiency genotypes identified in Germany and Italy are indicated. “Q0” denotes the “null” allele, in
which the AAT gene is interrupted by a stop codon and no functional protein is produced. “Rare” includes all alleles other than M, S,
and Z. Pi e proteinase inhibitor.
Disease awareness of alpha1-antitrypsin deficiency 1403Knowledge regarding AAT deficiency
Compared with the four other respiratory diseases that
respondents were asked about (COPD, sarcoidosis, cystic
fibrosis, and idiopathic pulmonary fibrosis), the level of
knowledge regarding AAT deficiency was lower in both
Germany and Italy (2.8 and 2.5 for AAT deficiency vs 3.7 and
3.6 for COPD). In both countries, pulmonologists scored
higher than internal medicine specialists (IMs) and generalTable 1 Composition of survey respondents by specialty,
practice setting, and the average number of COPD patients
seen per month.
Germany
(n Z 180)
Italy
(n Z 181)
Specialty
Pulmonology (n Z 60) (n Z 61)
Internal medicine specialist (n Z 60) (n Z 30)
GP (n Z 60) (n Z 90)
Practice setting
Hospital (n Z 30) (n Z 91)
Pulmonology (n Z 30) (n Z 61)
Internal medicine specialist e (n Z 30)
GP e e
Office (n Z 150) (n Z 90)
Pulmonology (n Z 30) e
Internal medicine specialist (n Z 60) e
GP (n Z 60) (n Z 90)
Average number of COPD patients/month
Less than 5 (n Z 8) (n Z 13)
6e20 (n Z 42) (n Z 52)
21e50 (n Z 69) (n Z 75)
More than 50 (n Z 61) (n Z 41)practitioners (GPs) (Germany: 3.5 vs 2.7 [IMs] and 2.4 [GPs];
Italy: 3.0 vs 2.4 [IMs] and 2.2 [GPs]). In addition, hospital-
based physicians in both countries had a greater awareness
of all of these respiratory conditions than did office-based
physicians.
Physicians in Germany rated their personal perception of
their awareness/knowledge of AAT deficiency higher than
their colleagues in Italy did (68% vs 51% reporting that they
had “very much” or “average” knowledge of the disorder).
Fig. 3 shows the percentage of pulmonologists, IMs, and GPs
who rated their extent of knowledge on AAT deficiency.
Among pulmonologists, the proportion who reported
knowing “very much” about the condition was 53% in Ger-
many and 26% in Italy, compared with 5% and 1%, respec-
tively, of GPs. Physicians in both countries were also
questioned on where they obtained their information on
AAT deficiency. German physicians reported to rely heavily
on the scientific literature (78%), whereas Italian re-
spondents were more likely to refer to textbooks (67%).
Almost half of the respondents in Germany (49%) and 42% in
Italy regarded scientific meetings and conferences as
beneficial in communicating additional information on AAT
deficiency.
Testing for AAT deficiency
The percentage of physicians testing for AAT deficiency was
found to be higher in Germany than in Italy. However, only
half of all the physicians surveyed in Germany and 36% in
Italy were testing patients regularly for the disorder.
Regardless of country, pulmonologists and hospital-based
physicians were seen to be driving AAT deficiency testing,
as opposed to primary care physicians. Over 90% of physi-
cians in Germany in these two groups currently test for AAT
deficiency. Testing rates among IMs, GPs, and office-based
physicians, on the other hand, were relatively low (Fig. 4).
When participants in the two countries were asked how
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Figure 3 Knowledge of lung disease caused by AAT deficiency, by specialty.
Percentage of respondents from three different disciplines in Germany and Italy who gave the answer indicated to the question,
“How much do you know about lung disease caused by AAT deficiency?”.
PUD e pulmonologists; IM e internal medicine specialists; GP e general practitioners.
1404 T. Greulich et al.often they tested for AAT deficiency, more than two-thirds
(72% in Germany and 62% in Italy) reported carrying out
between one and five tests per month. Moreover, the ma-
jority of physicians who were currently testing for AAT
deficiency primarily tested young COPD patients (<45
years) and family members of AAT-deficient individuals.
Only 18 and 25% of physicians in Italy and Germany,
respectively, responded that they performed testing on all
COPD and asthmatic patients (Table 2).
Reasons for not testing patients
When physicians who reported that they were not regularly
testing for AAT deficiency were asked their reasons for this,
the three most cited were: (1) the perception that the cost
of testing was too high, (2) the view that they were rarely0
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Figure 4 Physicians currently testing for AAT deficiency.
Percentage of respondents from three different disciplines in Ger
currently test for AAT deficiency?”.
PUD e pulmonologists; IM e internal medicine specialists; GP e geconsulted by these patients, and (3) that patients with AAT
deficiency would be referred to other specialists (Table 3).
Only 7e8% of the physicians responded that there was no
treatment available, and some cited uncertainty in the
interpretation of the results as a reason for not testing for
AAT deficiency (Germany, 10%; Italy, 6%; Table 3). Very few
responded that they had tested but never positively iden-
tified any patients.Physician communication with the laboratory
regarding AAT deficiency testing
When the physicians who were currently testing for
AAT deficiency were surveyed, all respondents regardless
of their specialty or setting reported having good0
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Table 2 The types of patients most commonly tested for
AAT deficiency by physicians.
Patient types tested for
AAT deficiency
Germany
Total
(n Z 90)
Italy
Total
(n Z 65)
All COPD 18% 25%
Young COPD (<45 years) 83% 77%
Family members with
AAT deficiency
69% 72%
Asthma 10% 23%
Bronchiectasis 39% 43%
Others 16% 17%
Disease awareness of alpha1-antitrypsin deficiency 1405communication with the laboratory carrying out the tests
(scoring, 3.3e3.4). There was, however, some disagree-
ment (scoring, 2.6e3.0) with the statement that sufficient
materials about the implications of a positive result for the
patient were provided by the laboratory.Physician communication with the patient
regarding AAT deficiency testing
With regard to the genetic counseling of patients, there
was little difference in attitudes between the physicians’
disciplines (pulmonologist, IM, GP, hospital or office based)
and the countries surveyed, none of whom felt either
strongly comfortable or uncomfortable with communicating
this information (scoring, 2.0e2.9). When it came to giving
advice to patients about prognosis, lifestyle changes, and
treatment, it was observed that, overall, the pulmonolo-
gists were more confident about giving the appropriate
advice (Germany, 1.8; Italy, 2.2), while GPs were less sure
about the right information and guidance to provide to
these patients (Germany, 2.9; Italy, 3.1). There was a
moderate perception among the disciplines in bothTable 3 Reasons for not testing for AAT deficiency.
Respondents who do not test
for AAT deficiency
Germany
(n Z 90)
Italy
(n Z 120)
Reason
There is no treatment
available for this disease
7% 8%
It takes too much time 14% 8%
The cost for testing is too high 31% 17%
I don’t see those patients 26% 31%
I refer them to other specialists 51% 45%
Tested many but never
found any
4% 4%
Interpretation of the test
result is not clear
10% 6%
Other 4% 10%
The reasons given by German and Italian physicians who were
not already testing for AAT deficiency are shown. The majority
of respondents were internal medicine specialists and general
practitioners, of whom many were office-based physicians.countries that patients are lost to follow-up between initial
screening and subsequent confirmatory tests (2.0e2.8).
Approaches to AAT deficiency testing
The survey results showed that physicians from both
countries are following the same testing protocols. Most
physicians expressed a clear tendency (66e70%) to perform
serum level testing first and request further testing for
severe deficiency in those individuals with reduced levels.
The remainder either sent the samples to a laboratory
specializing in AAT deficiency in Marburg or Pavia or to a
commercial laboratory (Fig. 5).
Treatment of patients who are positively diagnosed
The physicians from both countries were asked whether
they were currently treating their patients with augmen-
tation therapy. Very few stated that all positively diagnosed
patients were treated, however, approximately one-third
of those surveyed from both Germany and Italy said that
they sometimes offered this treatment.
Discussion
By evaluating the data from two national registries (Italy
and Germany) and two reference laboratories (Pavia and
Marburg), we can confirm that there is a significant delay
for AAT-deficient patients between symptom onset and the
time when the diagnosis is made, consistent with the
existing literature.14e17,19 Our data suggest that, compared
with nonhereditary COPD, knowledge regarding AAT defi-
ciency is relatively poor in Germany and Italy, particularly
among internists and general practitioners. While current
guidelines stress the need to test every COPD patient for
AAT deficiency,4,18 our data show that only 10e25% of
physicians do so. We identified the main reasons for not
testing to be the perception that AAT-deficient patients are
not seen routinely, that they should be transferred to a
specialist, and that testing procedures are too expensive.
Taken together, our data provide reasons why AAT defi-
ciency is still significantly under-recognized.
Among non-pulmonologists, the relatively low awareness
of AAT deficiency in comparison with other respiratory
diseases, as shown by our survey, is in accordance with the
findings of other studies. Taliercio et al. (2010) reported
that AAT deficiency may be overlooked by physicians,
especially GPs.29 Low disease awareness determines low
testing rates, and several studies have demonstrated a low
rate of testing and diagnosis for AAT deficiency.15e17,25,30
Pulmonologists should encourage members of their
extended multidisciplinary team to be alert to AAT defi-
ciency. This might increase testing rates among GPs, in-
ternists, and other office-based physicians.
In the absence of a neonatal screening program for AAT
deficiency in the general population, the opportunity to
test for the disorder only arises when patients experience
respiratory symptoms that prompt them to consult a
physician. However, the symptoms of COPD due to AAT
deficiency cannot be differentiated from those resulting
from nonhereditary COPD or asthma. It is important,
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Figure 5 Preferred approaches for AAT deficiency testing.
Percentage of respondents from Germany and Italy who gave the answer indicated to the question, “Which approach do you
prefer?”.
1406 T. Greulich et al.therefore, for healthcare professionals to bear in mind that
the diagnosis of AAT deficiency cannot be based on clinical
presentation alone, and that a specific test must be un-
dertaken. Guidelines state that all symptomatic patients
with COPD, emphysema, or asthma with airflow obstruction
that is not fully reversible should undergo specific testing
for AAT deficiency.4,18 However, our survey shows that the
majority of physicians currently testing for AAT deficiency
primarily test younger COPD patients (<45 years) and
family members of AAT-deficient patients, with only
10e25% testing all patients with COPD and asthma.
Evidently even those who are actively testing are not
necessarily doing so in accordance with the recommenda-
tions, which may be due to a belief that COPD symptoms in
younger patients are unusual, or that resources can be
saved by testing only a minority of patients.
Although textbooks and other scientific literature were
valuable sources of information for the countries surveyed
here, exposure to information at congresses and meetings
was also seen to be important for a large proportion of
respondents. Development of training materials to help
healthcare professionals understand AAT deficiency is
therefore likely to be beneficial. A more interactive
approach to continuing medical education programs,
perhaps via web-based modules that provide physicians
with feedback, or that allow them to compare their re-
sponses with those of their peers,31 might give clinicians a
greater awareness of the disorder. Such initiatives might
help improve physicians’ recall and acceptance of new
challenges,32 such as those posed by orphan diseases.
The full diagnostic protocol for AAT deficiency requires
determination of both the patient genotype and phenotype
(following the measurement of AAT levels in the blood),
which can be time consuming. This is reflected in our reg-
istry data from Germany and Italy that showed once a test
was initiated, the time needed to obtain a definitive diag-
nosis was in the order of 3e4 weeks. This considerable
time interval was due to repeated blood sampling in some
instances where there were errors with the initial collec-
tion process. Our results show that gene sequencing isassociated with an increase in time to report a diagnosis
when compared with genotyping alone. This delay was
more pronounced in Germany, where such samples must be
sent to another specialized laboratory. Furthermore,
because the initial sample was a DBS, full blood had to be
collected. For this reason, the test-initiating physician and
the patient had to be contacted, which in some instances
took more than a year. As a consequence, there is a time
lag introduced, mainly due to contacting the physician and
patient, the second collection of samples, the trans-
portation of samples and communication of the result be-
tween laboratories.
Differences exist between countries in their approach to
testing. In some countries, both genotyping and determi-
nation of the AAT concentration by nephelometry are done
simultaneously by the laboratory. In other locations, gen-
otyping is only carried out after the AAT level has been
quantified and found to be below a certain cutoff (typically
<1.0 g/L), which is more cost effective33 but may incur a
delay. This latter approach was favored by the majority of
physicians surveyed (overall, 68e78%). A proportion of re-
spondents (Germany, 20%; Italy, 14%) preferred to send
patient samples for analysis to a decentralized commercial
laboratory. Disseminating the information about preferred
qualified testing laboratories might streamline screening
protocols. Where standard algorithms are not practiced,
there lies a risk that patients will become lost to follow-up
during the course, for example, between initial serum level
measurements and confirmatory tests. In the survey, over
one-third of physicians in Germany and over half of physi-
cians in Italy expressed the view that loss of patients to
follow-up was an issue during AAT deficiency testing.
Previous reports have speculated that a further obstacle
to the diagnosis of AAT deficiency may be the clinician’s
lack of conviction that effective treatments exist for the
disorder,29 or that it may be too complicated or inade-
quate.19,34 However, this was not a major obstacle to
testing for the clinicians surveyed in this study.
Whenever AAT deficiency is suspected, the physician
must inform their patients of the need to be tested and
Disease awareness of alpha1-antitrypsin deficiency 1407obtain their consent to carry it out; necessary steps which
represent potential barriers to testing. Therefore, physi-
cians’ attitudes might represent a further barrier to the
provision of more frequent testing, for example, their
concerns surrounding the communication of information
about a genetic disease to their patients and their general
lack of training in genetic counseling.35 In agreement with
this, our survey showed that GPs, in particular, lacked some
confidence when discussing these issues with their patients.
The purpose of testing is to identify affected patients, as
well as family members, who either have AAT deficiency or
are heterozygous carriers. Carriers may be at increased risk
for developing lung or liver disease, and may be more
vulnerable to these diseases if exposed to further risk
factors, such as smoking and occupational hazards. It is
important that affected patients disclose their diagnoses to
family members. Studies of a Swedish cohort of AAT-
deficient individuals who were diagnosed at birth8
revealed that antismoking advice given later in life was
relatively successful; only a small proportion of individuals
(3% of questionnaire respondents) with confirmed PiS or PiZ
AAT deficiency started smoking as adults.36 In addition,
when compared with a non-AAT-deficient control group,
patients who had been diagnosed with AAT deficiency at
birth were significantly less likely to become smokers as
adults (p < 0.05)37 One can speculate that knowledge about
their disease prompted a behavioral response among the
AAT-deficient cohort which reduced the likelihood of them
starting to smoke. This illustrates the importance of making
genetic counseling widely available in conjunction with
testing, and here physicians can play a critical role.38
Although not cited as a major barrier in this study, in
some instances, low rates of testing might reflect a degree
of “testing fatigue” among clinicians,32 where they
perceive that routinely testing vast numbers of patients will
yield few positive results. However, when a targeted
approach is taken, which tests individuals who have COPD,
incompletely reversible responsive asthma, liver disease, or
if there is a family member with AAT deficiency, the
detection rate is elevated. A recent screen for AAT-
deficient patients in Ireland identified that, within the
general population, 14.8% of individuals had at least one
alpha1-PI gene mutation, and this figure was almost
doubled (27.1%) when targeted testing was undertaken.11 It
is predicted, therefore, that by screening all patients with
COPD, of whom an estimated 1e3% are expected to have
AAT deficiency,15 many more patients would be identified.
There still appears to be a widespread lack of awareness
about this disorder. Our data suggest that respiratory spe-
cialists and other healthcare professionals continue to face
hurdles in the testing and diagnosis of patients. An increase
in physician education about AAT deficiency, and the use of
simpler testing approaches, should prove beneficial and will
undoubtedly lead to more patients being identified.20
In summary, we confirm earlier data that show a signif-
icant delay for AAT deficiency patients between the onset
of symptoms and time of diagnosis. Reasons for this include
limited awareness and knowledge about AAT deficiency, the
finding that only a minority of physicians test in accordance
with recommended practice, as well as a number of issues
relating to the interpretation of test results. With a greater
understanding of the hurdles that stand in the way ofdiagnosing patients with AAT deficiency, it might be
possible to reduce time delays, enable patients to avoid risk
factors and commence therapy earlier.
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